The Management of Lymphoma in the Setting of Pregnancy.

Abstract:

:The diagnosis of lymphoma in pregnant patients poses a therapeutic challenge necessitating consideration of the developing fetus without compromise of therapy with curative potential for the mother. The decision to initiate therapy during pregnancy is heavily influenced by fetal, maternal, and disease-related factors, of which the most influential are the trimester at diagnosis, the stage, and aggressiveness of the disease and the presence of life-threatening symptoms. Recent data suggest that deferral of therapy until after the first trimester is desirable if it is perceived that postponement of therapy will not compromise maternal outcome. For some patients, delay of therapy to the postpartum period is feasible.

journal_name

Curr Hematol Malig Rep

authors

Pinnix CC,Andraos TY,Milgrom S,Fanale MA

doi

10.1007/s11899-017-0386-x

subject

Has Abstract

pub_date

2017-06-01 00:00:00

pages

251-256

issue

3

eissn

1558-8211

issn

1558-822X

pii

10.1007/s11899-017-0386-x

journal_volume

12

pub_type

杂志文章,评审
  • Leveraging Hypomethylating Agents for Better MDS Therapy.

    abstract:PURPOSE OF REVIEW:Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy. For those who do respond,...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-018-0477-3

    authors: Bradley TJ,Watts JM,Swords RT

    更新日期:2018-12-01 00:00:00

  • Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.

    abstract::The DNA hypomethylating agents (HMAs) azacitidine and decitabine are currently the most frequently administered disease-modifying therapies for patients with higher-risk myelodysplastic syndromes (MDS). However, azacitidine and decitabine are not curative, the median response duration is 11-15 months, and only 10-20 %...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-015-0273-2

    authors: Roberts DA,Steensma DP

    更新日期:2015-09-01 00:00:00

  • Artificial Intelligence in Hematology: Current Challenges and Opportunities.

    abstract:PURPOSE OF REVIEW:Artificial intelligence (AI), and in particular its subcategory machine learning, is finding an increasing number of applications in medicine, driven in large part by an abundance of data and powerful, accessible tools that have made AI accessible to a larger circle of investigators. RECENT FINDINGS:...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-020-00575-4

    authors: Radakovich N,Nagy M,Nazha A

    更新日期:2020-06-01 00:00:00

  • Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.

    abstract::Advances in drug discovery have led to the use of effective targeted agents in the treatment of hematologic malignancies. Drugs such as proteasome inhibitors in multiple myeloma and tyrosine kinase inhibitors in chronic myeloid leukemia and non-Hodgkin lymphoma have changed the face of treatment of hematologic maligna...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-017-0369-y

    authors: Sethi TK,Basdag B,Bhatia N,Moslehi J,Reddy NM

    更新日期:2017-06-01 00:00:00

  • Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics.

    abstract::Morphologic dysplasia is an important factor in diagnosis of myelodysplastic syndrome (MDS). However, the role of dysplasia is changing as new molecular genetic and genomic technologies take a more prominent place in diagnosis. This review discusses the role of morphology in the diagnosis of MDS and its interactions w...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-017-0405-y

    authors: Shaver AC,Seegmiller AC

    更新日期:2017-10-01 00:00:00

  • Polatuzumab Vedotin: a New Target for B Cell Malignancies.

    abstract:PURPOSE OF REVIEW:Antibody-drug conjugates are a new class of therapeutic agents in the treatment of B cell malignancies. In this review, we summarize the recent developments of polatuzumab vedotin in the treatment of relapsed or refractory diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). RECENT FIN...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-020-00572-7

    authors: Choi Y,Diefenbach CS

    更新日期:2020-04-01 00:00:00

  • Chemotherapy for patients with acute myeloid leukemia in first remission.

    abstract::Although the majority of patients with acute myeloid leukemia (AML) achieve a complete remission with induction chemotherapy, most will ultimately relapse. Therefore, the optimal postremission therapy for AML remains to be defined, and further improvements in treatment strategies are required. Clinical trials have dem...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-006-0021-8

    authors: Bradstock K

    更新日期:2006-06-01 00:00:00

  • What Does Chronic Myeloid Leukaemia Tell Us About Other Leukaemias?

    abstract:PURPOSE OF REVIEW:Determine if therapy of chronic myeloid leukaemia (CML) is a model for treating other cancers. RECENT FINDINGS:CML has a relatively homogeneous phenotype and genotype and is caused by one mutation, BCRABL1, in every instance. In contrast, most other leukaemias, haematologic cancers and solid cancer h...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-019-00555-3

    authors: Gale RP,Apperley J

    更新日期:2019-12-01 00:00:00

  • Navigating Ethical Practices in the Era of High Cost Hematology.

    abstract:PURPOSE OF REVIEW:In this review article, we will highlight ethical issues faced by hematologists due to a growing constellation of expensive diagnostics and therapeutics in hematology. We outline the important issues surrounding this topic including stakeholders, cost considerations, and various ethical challenges sur...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-020-00599-w

    authors: Ertz-Archambault N,Khera N

    更新日期:2020-10-01 00:00:00

  • Choosing Wisely® in Hematology: Have We Made a Difference?

    abstract:PURPOSE OF REVIEW:The Choosing Wisely® initiative, led by the American Board of Internal Medicine Foundation in collaboration with national professional medical societies, aims to help patients choose care that is essential, free from harm, and evidence-based. The American Society of Hematology has advocated practices ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-020-00593-2

    authors: Hilal T,Munoz J

    更新日期:2020-08-01 00:00:00

  • Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma.

    abstract:PURPOSE OF REVIEW:This article will review the use of anti-CD19 CAR-T therapy used in relapsed/refractory diffuse large B cell lymphoma. RECENT FINDINGS:The clinical outcomes, safety analysis, and other relevant considerations will be discussed with an emphasis on the most recently published data regarding the ZUMA-1,...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-018-0482-6

    authors: Havard R,Stephens DM

    更新日期:2018-12-01 00:00:00

  • Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.

    abstract::Multiple myeloma is a disorder of terminally differentiated plasma cells, characterized by immune dysfunction, deregulated signaling within the bone marrow stromal compartment, and a microenvironment that fosters immunosuppression. Immunomodulatory techniques, such as allogeneic hematopoietic stem cell transplant (all...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-015-0283-0

    authors: Karp Leaf R,Cho HJ,Avigan D

    更新日期:2015-12-01 00:00:00

  • Correction to: Strategies for Predicting Response to Checkpoint Inhibitors.

    abstract::The original version of this article unfortunately contained a mistake. The conflict of interest statement was incorrect. The corrected statement is given below. ...

    journal_title:Current hematologic malignancy reports

    pub_type: 已发布勘误

    doi:10.1007/s11899-018-0488-0

    authors: Zappasodi R,Wolchok JD,Merghoub T

    更新日期:2019-02-01 00:00:00

  • Lenalidomide in myelodysplastic syndromes: where do we go from here?

    abstract::Myelodysplastic syndromes (MDS), or myelodysplasia, are a heterogeneous group of bone marrow disorders characterized by progressive cytopenias and a propensity to evolve into acute leukemia. The only curative strategy in the treatment of MDS is stem cell transplantation. The advent of hypomethylating agents and, more ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章

    doi:10.1007/s11899-008-0002-1

    authors: Sirulnik LA,Stone RM

    更新日期:2008-01-01 00:00:00

  • The Future of Targeting FLT3 Activation in AML.

    abstract::Internal tandem duplications (ITD) and tyrosine-kinase domain (TKD) mutations of the FMS-like tyrosine-kinase 3 (FLT3) can be found in up to one third of patients with acute myeloid leukemia (AML) and confer a poor prognosis. First discovered 20 years ago, these mutations were identified as viable therapeutic targets,...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-017-0381-2

    authors: Leick MB,Levis MJ

    更新日期:2017-06-01 00:00:00

  • Quality of life in MPN comes of age as a therapeutic target.

    abstract::BCR-ABL-negative myeloproliferative neoplasms include primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Clonal stem cell proliferation and dysregulated JAK/STAT molecular pathways characterize these hematologic malignancies. Symptoms experienced by patients are heterogeneous including excessive ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-014-0239-9

    authors: Scherber RM,Geyer HL,Mesa RA

    更新日期:2014-12-01 00:00:00

  • Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?

    abstract::Acute myeloid leukemia (AML) is a very heterogeneous disease. Prognosis is related not only to intrinsic characteristics such as cytogenetics and molecular markers, but also the patient's ability to tolerate therapy, and treatment response. Allogeneic stem cell transplantation (allo-HCT) has been traditionally indicat...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-014-0207-4

    authors: Lekakis LJ,Cooper BW,de Lima MG

    更新日期:2014-06-01 00:00:00

  • Pathogenesis of Enteropathy-Associated T Cell Lymphoma.

    abstract:PURPOSE OF REVIEW:To provide an update on the pathogenesis of enteropathy-associated T cell lymphoma (EATL) and its relationship with refractory celiac disease (RCD), in light of current knowledge of immune, genetic, and environmental factors that promote neoplastic transformation of intraepithelial lymphocytes (IELs)....

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-018-0459-5

    authors: Chander U,Leeman-Neill RJ,Bhagat G

    更新日期:2018-08-01 00:00:00

  • Assessing Quality of Care for the Myelodysplastic Syndromes.

    abstract::Measuring the quality of care for patients with chronic cancers is difficult, especially for heterogeneous malignancies such as the myelodysplastic syndromes (MDS). Recent work suggests that improvements may be needed in the quality of diagnostic, treatment, and end-of-life care for patients with these syndromes. More...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-016-0343-0

    authors: Frosch ZA,Abel GA

    更新日期:2016-12-01 00:00:00

  • Oral Chemotherapy in Patients with Hematological Malignancies-Care Process, Pharmacoeconomic and Policy Implications.

    abstract::Patients with hematologic malignancies are increasing being prescribed oral anticancer medications (OAMs) and/or biologics. These newer targeted OAMs are associated with a host of practical and pharmacoeconomic implications for patients and healthcare providers. Issues such as safety, procurement challenges, and the n...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-016-0325-2

    authors: Betcher J,Dow E,Khera N

    更新日期:2016-08-01 00:00:00

  • Recognizing unusual manifestations of Hodgkin lymphoma.

    abstract::Hodgkin lymphoma (HL) is a rare malignancy of the lymphatic system that is curable in at least 80 % of patients. Although patients usually present with painless lymphadenopathy, a variety of systemic and organ-specific syndromes may also exist in relation to HL. These syndromes may develop before, during, or after the...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-012-0131-4

    authors: Barber NA,Bierman PJ

    更新日期:2012-09-01 00:00:00

  • PET in T-Cell Lymphoma.

    abstract::Most non-Hodgkin lymphomas (NHL) are of B-cell origin; only about 10% are T-cell or NK-cell lymphomas. The clinical features of T/NK-cell lymphomas differ from those of B-cell lymphomas: advanced stage and extranodal disease are more common and the prognosis is worse. Several studies have confirmed that 2-[fluorine-18...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章

    doi:10.1007/s11899-011-0098-6

    authors: Zinzani PL

    更新日期:2011-12-01 00:00:00

  • The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.

    abstract:PURPOSE OF REVIEW:Ruxolitinib is the first FDA-approved JAK inhibitor for the treatment of myeloproliferative neoplasms and is an effective means of controlling symptom burden and improving splenomegaly. However, a majority of patients will develop disease progression with long-term use. Fedratinib, momelotinib, and pa...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-020-00596-z

    authors: Patel AA,Odenike O

    更新日期:2020-12-01 00:00:00

  • Primary mediastinal large B-cell lymphoma.

    abstract::Primary mediastinal B-cell lymphoma (PMBCL) is a relatively rare lymphoma subtype affecting mainly young adults. Its molecular signature and clinical features resemble classical Hodgkin lymphoma. The optimal chemotherapy for this lymphoma subtype has not been established. The addition of rituximab to anthracycline bas...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章

    doi:10.1007/s11899-014-0219-0

    authors: Dabrowska-Iwanicka A,Walewski JA

    更新日期:2014-09-01 00:00:00

  • The Critical Role of Imaging in the Management of Multiple Myeloma.

    abstract::Multiple myeloma (MM) is characterized by abnormal proliferation of plasma cells in the bone marrow leading to symptoms of anemia, renal failure, hypercalcemia, and bone lesions. Bone imaging is critical for the diagnosis, staging, assessment for the presence and extent of bone lesions, and initial treatment of MM. Sk...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-017-0379-9

    authors: Raza S,Leng S,Lentzsch S

    更新日期:2017-06-01 00:00:00

  • Update on antigen-specific immunotherapy of acute myeloid leukemia.

    abstract::Among the few drugs that have shown a benefit for patients with acute myeloid leukemia (AML) in randomized clinical trials over the last several decades is the CD33 antibody-drug conjugate, gemtuzumab ozogamicin (GO). Undoubtedly, this experience has highlighted the value of antigen-specific immunotherapy in AML. A wi...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-015-0250-9

    authors: Buckley SA,Walter RB

    更新日期:2015-06-01 00:00:00

  • The Effect of Psychosocial Interventions on Outcomes for Caregivers of Hematopoietic Cell Transplant Patients.

    abstract:PURPOSE OF REVIEW:Hematopoietic cell transplant (HCT) patients are required to have a caregiver present for up to 100 days post-transplant. Caregivers provide essential support during HCT but experience immense stress and burden. Increasing research has developed interventions for HCT caregivers. This review systematic...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-018-0445-y

    authors: Bangerter LR,Griffin JM,Langer S,Hasan B,Kim WS,Murad MH,Khera N

    更新日期:2018-06-01 00:00:00

  • Who Should Receive a Transplant for Acute Lymphoblastic Leukaemia?

    abstract::Allogeneic haematopoietic cell transplantation continues to be an important curative therapy for acute lymphoblastic leukaemia (ALL). Traditionally accepted indications for allografting adult ALL patients need reevaluation in light of outcomes with paediatric-like intensive regimens. Minimal residual disease status an...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-017-0371-4

    authors: Dhawan R,Marks DI

    更新日期:2017-04-01 00:00:00

  • Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy.

    abstract:PURPOSE OF REVIEW:CMV DNA polymerase inhibitors such as ganciclovir and foscarnet have dramatically reduced the burden of CMV infection in the HCT recipient. However, their use is often limited by toxicities and resistance. Agents with novel mechanisms and favorable toxicity profiles are critically needed. We review re...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-020-00557-6

    authors: Hakki M

    更新日期:2020-04-01 00:00:00

  • Early interim PET scans in diffuse large B-cell lymphoma: can there be consensus about standardized reporting, and can PET scans guide therapy choices?

    abstract::The prognosis value of interim positron emission tomography (PET) remains controversial in diffuse large B-cell lymphoma (DLBCL) patients because of the absence of consensus on criteria able to early identify good and bad responders to treatment. Visual interpretation using the International Harmonization Project (IHP...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-012-0129-y

    authors: Casasnovas RO,Meignan M,Berriolo-Riedinger A,Itti E,Huglo D,Haioun C,Morschhauser F

    更新日期:2012-09-01 00:00:00